Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $25.22 up 0.88% from its previous closing price of $25.00. In other words, the price has increased by $0.88 from its previous closing price. On the day, 0.91 million shares were traded. ARWR stock price reached its highest trading level at $25.27 during the session, while it also had its lowest trading level at $24.3.
Ratios:
For a deeper understanding of Arrowhead Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.73. In the meantime, Its Debt-to-Equity ratio is 2.45 whereas as Long-Term Debt/Eq ratio is at 2.42.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 04, 2023, initiated with a Buy rating and assigned the stock a target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 02 ’24 when Vakiener Victoria sold 1,799 shares for $23.31 per share. The transaction valued at 41,935 led to the insider holds 30,205 shares of the business.
Hamilton James C sold 6,000 shares of ARWR for $168,180 on Apr 01 ’24. The Chief Discovery/Trans Medicine now owns 204,851 shares after completing the transaction at $28.03 per share. On Mar 20 ’24, another insider, Lu Hongbo, who serves as the Director of the company, bought 1,000 shares for $27.50 each. As a result, the insider paid 27,500 and bolstered with 33,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 3124682240 and an Enterprise Value of 3289620736. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.19 while its Price-to-Book (P/B) ratio in mrq is 16.90. Its current Enterprise Value per Revenue stands at 18.101 whereas that against EBITDA is -11.529.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $41.36, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is -7.12%, while the 200-Day Moving Average is calculated to be -11.94%.
Shares Statistics:
For the past three months, ARWR has traded an average of 1.23M shares per day and 834290 over the past ten days. A total of 123.90M shares are outstanding, with a floating share count of 117.77M. Insiders hold about 4.95% of the company’s shares, while institutions hold 64.92% stake in the company. Shares short for ARWR as of 1713139200 were 8866496 with a Short Ratio of 7.23, compared to 1710460800 on 9202756. Therefore, it implies a Short% of Shares Outstanding of 8866496 and a Short% of Float of 8.4.
